Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance; Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study; Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells; Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy; Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a …; Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors; Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models; Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised …; Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma; Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial; An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling; PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas; The mitogen-activated protein kinase pathway in melanoma part I–activation and primary resistance mechanisms to BRAF inhibition; A stress-induced early innate response causes multidrug tolerance in melanoma; BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth; A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma; Personalized preclinical trials in BRAF inhibitor–resistant patient-derived xenograft models identify second-line combination therapies; Tumor-associated B-cells induce tumor heterogeneity and therapy resistance; MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines; The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells
